These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20920923)

  • 21. Magnesium sulfate administration in subarachnoid hemorrhage.
    Suarez JI;
    Neurocrit Care; 2011 Sep; 15(2):302-7. PubMed ID: 21748496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pathogenesis of cerebral vasospasm after subarachnoid hemorrhage].
    Tamura Y; Ohta T; Ogawa R; Ozaki M; Suyama Y
    No To Shinkei; 2000 Jun; 52(6):461-7. PubMed ID: 10875116
    [No Abstract]   [Full Text] [Related]  

  • 23. Erythropoietin: will it improve outcome after subarachnoid hemorrhage?
    Macdonald RL
    World Neurosurg; 2010 May; 73(5):463-4. PubMed ID: 20920924
    [No Abstract]   [Full Text] [Related]  

  • 24. Vasodilation and neuroprotection: the magnesium saga in subarachnoid hemorrhage.
    Taccone FS
    Crit Care Med; 2010 May; 38(5):1382-4. PubMed ID: 20404634
    [No Abstract]   [Full Text] [Related]  

  • 25. Use of intrathecal nicardipine for aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm.
    Ehtisham A; Taylor S; Bayless L; Samuels OB; Klein MW; Janzen JM
    South Med J; 2009 Feb; 102(2):150-3. PubMed ID: 19139684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of recombinant osteopontin on cerebral vasospasm after subarachnoid hemorrhage in rats.
    Suzuki H; Hasegawa Y; Kanamaru K; Zhang JH
    Acta Neurochir Suppl; 2011; 110(Pt 2):29-32. PubMed ID: 21125441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythropoietin prevents delayed hemodynamic dysfunction after subarachnoid hemorrhage in a randomized controlled experimental setting.
    Güresir E; Vasiliadis N; Konczalla J; Raab P; Hattingen E; Seifert V; Vatter H
    J Neurol Sci; 2013 Sep; 332(1-2):128-35. PubMed ID: 23907045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of intraventricular thrombolysis in combination with low-frequency head motion after severe subarachnoid hemorrhage: interim analysis of safety, clot clearance rate and delayed cerebral ischemia.
    Eicker SO; Beseoglu K; Etminan N; Perrin J; Taskin A; Steiger HJ; Hänggi D
    Acta Neurochir Suppl; 2012; 114():323-8. PubMed ID: 22327716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The present role of "triple-H" therapy in the management of cerebral vasospasm.
    Findlay JM
    World Neurosurg; 2010; 74(2-3):244-6. PubMed ID: 21492545
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment modality and vasospasm after aneurysmal subarachnoid hemorrhage.
    Gross BA; Rosalind Lai PM; Frerichs KU; Du R
    World Neurosurg; 2014 Dec; 82(6):e725-30. PubMed ID: 23954735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distribution of delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage and implications for regional neuromonitoring.
    Miller CM; Palestrant D
    Clin Neurol Neurosurg; 2012 Jul; 114(6):545-9. PubMed ID: 22176917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Letter: Clinical Benefit of Clazosentan in Vasospasm After Subarachnoid Hemorrhage: Are We There Yet?
    Katiyar V; Kale A; Sharma R; Ganeshkumar A; Borkar SA
    Neurosurgery; 2023 Feb; 92(2):e37-e40. PubMed ID: 36637286
    [No Abstract]   [Full Text] [Related]  

  • 33. Preface. Aneurysmal subarachnoid hemorrhage.
    Nyquist P; Naval N; Tamargo RJ
    Neurosurg Clin N Am; 2010 Apr; 21(2):xiii-xiv. PubMed ID: 20380964
    [No Abstract]   [Full Text] [Related]  

  • 34. Recommendations for the management of medical complications in patients following aneurysmal subarachnoid hemorrhage.
    Solter VV; Roje-Bedeković M; Breitenfeld T; Supanc V; Lovrencić-Huzjan A; Serić V; Antoncić I; Basić S; Beros V; Bielen I; Soldo SB; Kadojić D; Lusić I; Maldini B; Marović A; Paladino J; Poljaković Z; Radanović B; Rados M; Rotim K; Vukić M; Zadravec D; Kes VB
    Acta Clin Croat; 2014 Mar; 53(1):113-38. PubMed ID: 24974675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anemia and transfusion after aneurysmal subarachnoid hemorrhage.
    Rosenberg NF; Koht A; Naidech AM
    J Neurosurg Anesthesiol; 2013 Jan; 25(1):66-74. PubMed ID: 23047622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of delayed ischemic neurologic deficit following aneurysmal subarachnoid hemorrhage: historical overview, current treatment, and pathophysiology.
    Al-Tamimi YZ; Orsi NM; Quinn AC; Homer-Vanniasinkam S; Ross SA
    World Neurosurg; 2010 Jun; 73(6):654-67. PubMed ID: 20934153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transient oculomotor nerve palsy after topical administration of intracisternal papaverine.
    Chittiboina P; Willet O; Nanda A; Guthikonda B
    Acta Neurochir (Wien); 2011 Feb; 153(2):431-3. PubMed ID: 21076927
    [No Abstract]   [Full Text] [Related]  

  • 38. Cerebral vasospasm after aneurysmal subarachnoid hemorrhage: an overview of pharmacologic management.
    Liu-Deryke X; Rhoney DH
    Pharmacotherapy; 2006 Feb; 26(2):182-203. PubMed ID: 16466324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg 98:978-984, May, 2003.
    Egge A; Waterloo K; Sjøholm H; Solberg T; Ingebrigtsen T; Romner B
    J Neurosurg; 2004 Feb; 100(2):359-60; author reply 360. PubMed ID: 15086250
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
    Schmid-Elsaesser R; Kunz M; Zausinger S; Prueckner S; Briegel J; Steiger HJ
    Neurosurgery; 2006 Jun; 58(6):1054-65; discussion 1054-65. PubMed ID: 16723884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.